Recovery of pad-free continence in elderly men does not differ from younger men undergoing robot-assisted radical prostatectomy for aggressive prostate cancer.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 17 03 2019
accepted: 30 04 2019
pubmed: 13 5 2019
medline: 15 12 2020
entrez: 13 5 2019
Statut: ppublish

Résumé

To analyze urinary continence outcome following robot-assisted radical prostatectomy (RARP) for aggressive prostate cancer in men aged ≥ 70 and < 70 years. Retrospective analyses of prospectively collected long-term data from a monocentric cohort of 350 men with D'Amico high-risk prostate cancer undergone robot-assisted radical prostatectomy at a single institution between 2005 and 2016. The association between time since operation and zero-pad urinary continence recovery was comparatively analyzed by separate pre-operative and post-operative Cox proportional-hazard regression models. Median age in the age group ≥ 70 years was 73 years compared with 62 years in the < 70 year age group. Distribution of men receiving adjuvant and salvage radiotherapy/hormonal therapy was similar in both age groups. Urinary continence recovery rate at 12, 24, and 36 months after surgery of men aged ≥ 70 years was 66, 79 and 83%, respectively, and statistically similar to that of men < 70 years: 71, 81, and 85% (log-rank test p = 0.24). Multivariable analyses demonstrated no significant difference in return to continence between the two age groups (p = 0.28 and p = 0.17). In addition, clinical stage and type of nerve sparing (unilateral, bilateral or non-nerve sparing) were found to be independently predictive of pad-free continence recovery. Regardless of age, return to continence in men with aggressive prostate cancer undergoing RARP continues to improve way beyond the first 12 months after surgery. Considering the dire effects of post-operative radiotherapy on continence in this aggressive cancer cohort, advanced age alone should not discourage recommending multimodal therapy involving RARP.

Identifiants

pubmed: 31079187
doi: 10.1007/s00345-019-02797-5
pii: 10.1007/s00345-019-02797-5
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

351-360

Commentaires et corrections

Type : CommentIn

Références

Eur J Surg Oncol. 2015 Jul;41(7):837-43
pubmed: 25980748
J Robot Surg. 2007;1(2):139-43
pubmed: 25484950
Trends Neurosci. 2006 Oct;29(10):587-99
pubmed: 16942805
BJU Int. 2013 Mar;111(3 Pt B):E24-9
pubmed: 22947135
Virchows Arch. 2010 Dec;457(6):741-7
pubmed: 20978804
J Endourol. 2017 Mar;31(3):229-237
pubmed: 28006957
J Urol. 2004 Dec;172(6 Pt 1):2227-31
pubmed: 15538237
BJU Int. 2014 Nov;114 Suppl 1:29-33
pubmed: 24825396
Urol Oncol. 2013 Feb;31(2):193-7
pubmed: 21803614
Adv Urol. 2012;2012:702412
pubmed: 22924039
Eur Urol. 2012 Sep;62(3):405-17
pubmed: 22749852
Eur Urol Focus. 2020 Nov 15;6(6):1205-1212
pubmed: 30477971
JAMA. 2018 May 8;319(18):1901-1913
pubmed: 29801017
J Robot Surg. 2007;1(2):125-32
pubmed: 25484948
Prostate Cancer Prostatic Dis. 2017 Dec;20(4):395-400
pubmed: 28462944
J Urol. 1998 Jan;159(1):158-63
pubmed: 9400461
Ann Surg. 1980;192(4):465-71
pubmed: 7425693
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Rev Urol. 2008 Spring;10(2):111-9
pubmed: 18660852
World J Urol. 2016 Jan;34(1):113-20
pubmed: 25991601
J Urol. 2003 Dec;170(6 Pt 1):2374-8
pubmed: 14634420
Eur Urol. 2009 Sep;56(3):472-8
pubmed: 19560260
Urology. 2006 Aug;68(2):249-52
pubmed: 16904428
Urology. 2003 Apr;61(4):699-702
pubmed: 12670546
J Urol. 1999 Aug;162(2):433-8
pubmed: 10411052
BJU Int. 2015 Nov;116(5):764-70
pubmed: 25726729
Urol Oncol. 2012 Jan-Feb;30(1):26-32
pubmed: 20189844
BJU Int. 2006 Jun;97(6):1234-41
pubmed: 16686718
BJU Int. 2009 Nov;104(10):1492-5
pubmed: 19583731

Auteurs

Joanne Nyaboe Nyarangi-Dix (JN)

Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.

Georgi Tosev (G)

Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany. georgi.tosev@med.uni-heidelberg.de.

Ivan Damgov (I)

Freelance Statistical Consultant, Sofia, Bulgaria.

Philipp Reimold (P)

Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.

Cem Aksoy (C)

Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.

Gencay Hatiboglu (G)

Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.

Dogu Teber (D)

Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.

Josef Mansour (J)

Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.

Franklin Emmanuel Kuehhas (FE)

Consultant Urologist, Stadiongasse 6-8/30, 1010, Vienna, Austria.

Jan Philipp Radtke (JP)

Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.
Department of Radiology, German Cancer Research Center, Heidelberg, Germany.

Markus Hohenfellner (M)

Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH